Teva R&D Spending Target Raised To 7.5% Of Sales
Executive Summary
Teva Pharmaceuticals will boost research and development spending this year toward a new goal of 7.5 percent of sales, company executives announced during the firm's fourth quarter earnings call Feb. 12
You may also be interested in...
Roche Mantra Is “Pipeline, Pipeline, Pipeline;” R&D Surge Continues In 2008
Roche spending increases on pharmaceutical research and development will continue to outpace sales gains in 2008, company executives said during the firm's fourth quarter financial review Jan. 30
Teva Bulks Up Biopharma With $400 Million CoGenesys Acquisition
Teva Pharmaceuticals will acquire the privately held biopharma CoGenesys for $400 million in an effort to strengthen its biogenerics position, the company announced Jan. 22
Teva Throws Wyeth Year-End Curve Ball With Launch Of Generic Protonix
Teva's launch of a generic version of Wyeth's proton pump inhibitorProtonix (pantoprazole) means that Wyeth must quickly decide how much faith to place in its patent as it negotiates a potential settlement